Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse Model.

Autor:	Goshima T; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.; Department of Pediatric Surgery, The University of Tokyo Hospital, Tokyo, Japan., Ieguchi K; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Onishi N; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Shimizu T; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Takayanagi D; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Watanabe M; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Fujimoto Y; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Ohkuma R; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Suzuki R; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Tsurui T; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.; Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Mura E; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Iriguchi N; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Ishiguro T; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Shimokawa M; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Hirasawa Y; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Kubota Y; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Ariizumi H; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Horiike A; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Yoshimura K; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Clinical ImmunoOncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Tsuji M; Pharmacological Research Center, Showa University, Tokyo, Japan., Kiuchi Y; Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Kobayashi S; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Fujishiro J; Department of Pediatric Surgery, The University of Tokyo Hospital, Tokyo, Japan., Hoffman RM; AntiCancer Inc., San Diego, CA, U.S.A.; Department of Surgery, University of California, San Diego, CA, U.S.A., Tsunoda T; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Wada S; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan; st-wada@med.showa-u.ac.jp.; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2024 Jan; Vol. 44 (1), pp. 23-29.
DOI:	10.21873/anticanres.16784
Abstrakt:	Background/aim: The response rate to immune checkpoint inhibitors (ICIs) is approximately 10%-30% and only in a few cancer types. In the present study, we determined whether non-classical monocytes (NCMs) could enhance ICI efficacy in colon cancer using a syngeneic mouse model. Materials and Methods: The MC38 C57BL/6 mouse colon cancer model was used. Cells collected from the bone marrow of C57BL/6 mice were cultured, and NCMs were fractionated by cell sorting and administered via the tail veins to the mice implanted with MC38 cells. The anti-mouse PD-L1 antibody was administered three times, and tumor volume and overall survival were observed. Results: More tumors were eradicated and more complete response occurred, after cotreatment with ICIs and NCMs than after treatment with ICIs alone. Moreover, no efficacy was observed when NCMs were administered alone. Conclusion: NCMs enhance ICI efficacy. The underlying mechanisms and clinical applications will be studied in the future. (Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu